RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Pratibha V. Nerurkar to Humans

This is a "connection" page, showing publications Pratibha V. Nerurkar has written about Humans.
Connection Strength

0.210
  1. Nerurkar PV, Gandhi K, Chen JJ. Correlations between Coffee Consumption and Metabolic Phenotypes, Plasma Folate, and Vitamin B12: NHANES 2003 to 2006. Nutrients. 2021 Apr 18; 13(4).
    View in: PubMed
    Score: 0.037
  2. Nerurkar PV, Hwang PW, Saksa E. Anti-Diabetic Potential of Noni: The Yin and the Yang. Molecules. 2015 Sep 25; 20(10):17684-719.
    View in: PubMed
    Score: 0.025
  3. Nerurkar PV, Nishioka A, Eck PO, Johns LM, Volper E, Nerurkar VR. Regulation of glucose metabolism via hepatic forkhead transcription factor 1 (FoxO1) by Morinda citrifolia (noni) in high-fat diet-induced obese mice. Br J Nutr. 2012 Jul; 108(2):218-228.
    View in: PubMed
    Score: 0.019
  4. Snee LS, Nerurkar VR, Dooley DA, Efird JT, Shovic AC, Nerurkar PV. Strategies to improve palatability and increase consumption intentions for Momordica charantia (bitter melon): a vegetable commonly used for diabetes management. Nutr J. 2011 Jul 28; 10:78.
    View in: PubMed
    Score: 0.019
  5. Nerurkar PV, Lee YK, Nerurkar VR. Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complement Altern Med. 2010 Jun 29; 10:34.
    View in: PubMed
    Score: 0.017
  6. Nerurkar P, Ray RB. Bitter melon: antagonist to cancer. Pharm Res. 2010 Jun; 27(6):1049-53.
    View in: PubMed
    Score: 0.017
  7. Ray RB, Raychoudhuri A, Steele R, Nerurkar P. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res. 2010 Mar 01; 70(5):1925-31.
    View in: PubMed
    Score: 0.017
  8. Nerurkar PV, Lee YK, Linden EH, Lim S, Pearson L, Frank J, Nerurkar VR. Lipid lowering effects of Momordica charantia (Bitter Melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2. Br J Pharmacol. 2006 Aug; 148(8):1156-64.
    View in: PubMed
    Score: 0.013
  9. Nerurkar PV, Pearson L, Efird JT, Adeli K, Theriault AG, Nerurkar VR. Microsomal triglyceride transfer protein gene expression and ApoB secretion are inhibited by bitter melon in HepG2 cells. J Nutr. 2005 Apr; 135(4):702-6.
    View in: PubMed
    Score: 0.012
  10. Nerurkar PV, Dragull K, Tang CS. In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones. Toxicol Sci. 2004 May; 79(1):106-11.
    View in: PubMed
    Score: 0.011
  11. Nerurkar PV, Pearson L, Frank JE, Yanagihara R, Nerurkar VR. Highly active antiretroviral therapy (HAART)-associated lactic acidosis: in vitro effects of combination of nucleoside analogues and protease inhibitors on mitochondrial function and lactic acid production. Cell Mol Biol (Noisy-le-grand). 2003 Dec; 49(8):1205-11.
    View in: PubMed
    Score: 0.011
  12. Rajamoorthi A, Shrivastava S, Steele R, Nerurkar P, Gonzalez JG, Crawford S, Varvares M, Ray RB. Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-Met signaling. PLoS One. 2013; 8(10):e78006.
    View in: PubMed
    Score: 0.005
  13. Ru P, Steele R, Nerurkar PV, Phillips N, Ray RB. Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model. Cancer Prev Res (Phila). 2011 Dec; 4(12):2122-30.
    View in: PubMed
    Score: 0.005
  14. Le Marchand L, Hankin JH, Pierce LM, Sinha R, Nerurkar PV, Franke AA, Wilkens LR, Kolonel LN, Donlon T, Seifried A, Custer LJ, Lum-Jones A, Chang W. Well-done red meat, metabolic phenotypes and colorectal cancer in Hawaii. Mutat Res. 2002 Sep 30; 506-507:205-14.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support